Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC

  • BioNTech SE (NASDAQ:BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to its FixVac candidate BNT116 combined with Libtayo (cemiplimab) in advanced non-small-cell lung cancer (NSCLC). 
  • Under the terms of the agreement, the companies plan to jointly conduct clinical trials to evaluate the combination in different patient populations with advanced NSCLC and share development costs equally. 
  • Regeneron and Sanofi SA (NASDAQ: SNY) are jointly developing Libtayo.
  • The investigational mRNA-based cancer vaccine BNT116 is based on BioNTech's FixVac platform. 
  • It consists of a fixed combination of shared tumor-associated antigens that were identified to be frequently expressed in NSCLC. 
  • The companies plan to develop the collaboration beginning with Phase 1/2 clinical trials in the first-line treatment setting in advanced NSCLC. 
  • Additionally, under a separate agreement, BioNTech plans to conduct and sponsor a Phase 1 LuCa-MERIT-1 trial evaluating the combination of BNT116 and Libtayo in further subpopulations with NSCLC.
  • Price Action: BNTX shares are down 1.35% at $124.55, REGN stock is down 0.68% at $614.38 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.